# Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

> **NCT03945188** · PHASE3 · COMPLETED · sponsor: **Arena Pharmaceuticals** · enrollment: 433 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Etrasimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03945188
- **Lead sponsor:** Arena Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-13
- **Primary completion:** 2022-02-08
- **Final completion:** 2022-02-16
- **Target enrollment:** 433 (ACTUAL)
- **Last updated:** 2022-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03945188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03945188, "Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03945188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*